Abstract 2059: Co-treatment of XL019, a selective Jak2 inhibitor, highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-2059
Abstract: 1 Co-treatment of XL019, a selective Jak2 inhibitor, highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition Ji Hyun Cheon1, Yu Jin Park, Ji Yeon Son, Sung Pil Yoon, and Hyung Sik Kim Lab of… read more here.
Keywords: xl019; inhibition; cancer cells; cancer ... See more keywords
A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2018.01379
Abstract: The JAK2/STAT signaling pathway mediates cytokine receptor signals that are involved in cell growth, survival and homeostasis. JAK2 is a member of the Janus kinase (JAK) family and aberrant JAK2/STAT is involved with various diseases,… read more here.
Keywords: inhibitor; compound nsc13626; pharmacological interactions; selective jak2 ... See more keywords
Jak2 Inhibitor AG490 Improved Poststroke Central and Peripheral Inflammation and Metabolic Abnormalities in a Rat Model of Ischemic Stroke
Sign Up to like & getrecommendations! Published in 2021 at "Antioxidants"
DOI: 10.3390/antiox10121958
Abstract: Poststroke hyperglycemia and inflammation have been implicated in the pathogenesis of stroke. Janus Kinase 2 (Jak2), a catalytic signaling component for cytokine receptors such as Interleukin-6 (IL-6), has inflammatory and metabolic properties. This study aimed… read more here.
Keywords: jak2 inhibitor; inhibitor ag490; inflammation metabolic; rat model ... See more keywords